Physician profile
Dwayne A Schmidt
NPI 1568453835
$8,168.12
in general payments reported to CMS, 2019-2025
42 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,651 · 2020: $938 · 2021: $1,549 · 2022: $1,147 · 2023: $1,112 · 2024: $528 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,412.70 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,279.00 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $1,254.02 | 2019-2020 | |
| Medtronic, INC. | $747.29 | 2021-2023 | Azure Xt Dr Mri Surescan, Selectsecure, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $505.29 | 2020-2025 | Dragonfly Opstar, Cardiomems, Pressurewire |
| Astrazeneca Pharmaceuticals Lp | $501.37 | 2019-2023 | Farxiga |
| Philips North America LLC | $302.85 | 2019-2022 | |
| Amarin Pharma, INC. | $219.54 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $207.41 | 2019-2022 | |
| Amgen INC. | $173.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $143.74 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $138.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.54 | 2019-2024 | Camzyos |
| Astellas Pharma US INC | $105.58 | 2019-2021 | |
| Chiesi USA, INC. | $91.04 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $87.62 | 2022-2024 | Barostim Neo System |
| Veryan Medical Incorporated | $80.05 | 2022-2024 | Biomimics 3d Vascular Stent System |
| Novo Nordisk INC | $70.54 | 2021-2022 | |
| Esperion Therapeutics, INC. | $63.78 | 2021 | |
| Lundbeck LLC | $61.97 | 2019 | |
| Baxter Healthcare | $58.17 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $46.59 | 2019-2022 | |
| Kerecis Limited | $45.10 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kestra Medical Technology Services, INC. | $43.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $36.32 | 2023 | Verquvo |
| Biotronik INC. | $36.23 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $28.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.16 | 2019-2021 | |
| Shockwave Medical, INC | $24.38 | 2022 | |
| Gilead Sciences, INC. | $23.74 | 2019 | |
| Endologix LLC | $23.72 | 2025 | Endocross Device, Torus Stent Graft System |
| Boston Scientific Corporation | $23.51 | 2019-2020 | |
| Smith+Nephew, INC. | $19.06 | 2021 | |
| Angiodynamics, INC. | $18.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.89 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.74 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.32 | 2024 | |
| Irhythm Technologies, INC. | $16.62 | 2020 | |
| Bardy Diagnostics, INC. | $13.79 | 2021 | |
| Althera Pharmaceuticals LLC | $5.95 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.